A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary EffiCacy Study of K201 Oral for the Prevention of ATrial FIbrillation (AF) Recurrence in Subjects Post-Conversion From AF.

Trial Profile

A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary EffiCacy Study of K201 Oral for the Prevention of ATrial FIbrillation (AF) Recurrence in Subjects Post-Conversion From AF.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2014

At a glance

  • Drugs JTV 519 (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARCTIC-AF
  • Sponsors Sequel Pharmaceuticals
  • Most Recent Events

    • 13 May 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 19 Nov 2010 Actual initiation date (April 2010) added as reported by ClinicalTrials.gov
    • 19 Nov 2010 Planned End Date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top